Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Study Published: PharmaPoint: Hemophilia A and B - Germany Drug Forecast and Market Analysis to 2022


Print article Print article
2014-01-23 21:03:43 - New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Full Report Details at
- www.fastmr.com/prod/764047_pharmapoint_hemophilia_a_and_b_german ..

GlobalData's primary research indicates that rates of plasma-derived replacement factors are higher in Germany compared with the other 5EU

and US markets. Market growth in Germany will be driven as well by increased rates of switching of patients from plasma-derived to recombinant factors during the forecast period.

Scope

* Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on the key drugs in Germany including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for the top drugs in Germany from 2012-2022.
* Analysis of the impact of key events as well the drivers and restraints affecting Germany Hemophilia A and B market.

Reasons to Get this Report

* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of drug performance
* Obtain sales forecast for drugs from 2012-2022 in Germany

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis and Quality of Life
3.2 Symptoms
3.2.1 Hemophilia A and B
3.2.2 Inhibitors
4 Disease Management
4.1 Treatment Overview
4.1.1 Hemophilia A and B Diagnosis
4.1.2 Hemophilia A and B Treatment
4.1.3 Inhibitors Diagnosis
4.1.4 Inhibitors Treatment
4.2 Germany
4.2.1 Clinical Practice
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitive Assessment
5.3 Product Profiles - Major Brands, Hemophilia A
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant))
5.3.3 Xyntha/ReFacto AF (moroctocog alfa; Antihemophilic Factor [Recombinant], Plasma/Albumin-Free)
5.3.4 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free)
5.4 Product Profiles - Hemophilia B
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant])
5.4.2 Rixubis (BAX-326)
5.5 Product Profiles - Hemophilia A and B with Inhibitors
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant])
6 Opportunity and Unmet Need
6.1 Overview
6.2 Opportunities Analysis
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections
6.2.2 Lower-Cost Recombinant Replacement Therapies
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients
6.2.4 More Convenient Drug Administration
6.2.5 Oral Formulation of Recombinant Replacement Therapies
6.3 Unmet Needs Gap Analysis
6.3.1 Long-Acting FVIII Replacement Therapies
6.3.2 Gene Therapy Treatments for Hemophilia A and B
7 Pipeline Assessment
7.1 Overview
7.2 Promising Drugs in Clinical Development - Hemophilia A
7.2.1 Eloctate (rFVIII-Fc) (recombinant factor VIII fusion protein)
7.2.2 BAY 94-9027 (octocog alfa)
7.2.3 BAX-855
7.2.4 Novoeight (turoctocog alfa; NN7008)
7.2.5 N8-GP (NN7088)
7.2.6 CSL-627 (rFVIII-SC)
7.2.7 Hcl-rhFVIII
7.3 Promising Drugs in Clinical Development - Hemophilia B
7.3.1 Alprolix (rFIXFc)
7.3.2 CSL-654 (rIX-FP)
7.3.3 N9-GP (NN-7999)
7.3.4 IB1001 (trenacog alfa)
7.4 Promising Drugs in Clinical Development - Hemophilia A and B Patients with Inhibitors
7.4.1 BAX-817 (rFVIIa BI)
8 Market Outlook
8.1 Germany
8.1.1 Forecast
8.1.2 Key Events
8.1.3 Drivers and Barriers
9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Methodology
9.4 Forecasting Methodology
9.4.1 Diagnosed Hemophilia Patients
9.4.2 Percent Drug-Treated Patients
9.4.3 Drugs Included in Each Therapeutic Class
9.4.4 Launch and Patent Expiry Dates
9.4.5 General Pricing Assumptions
9.4.6 Individual Drug Assumptions
9.4.7 Pricing of Pipeline Agents
9.5 Physicians and Specialists Included in this Study
9.6 About the Authors
9.6.1 Authors
9.6.2 Global Head of Healthcare
9.7 About GlobalData
9.8 Disclaimer

List of Tables

1.1 List of Tables
Table 1: Symptoms of Hemophilia A and B

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=764047&dt=t

About GlobalData

GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com